differentiated indications has been initiated by the company to further explore the efficacy of the product, such as HANSIZHUANG plus bevacizumab and chemotherapy as first-line treatment for patients with metastatic colorectal cancer (mCRC) , HANSIZHUANG plus chemotherapy as neoadjuvant/adjuvant therapy ...
A different, oral PARP inhibitor was also tested in women with metastatic breast cancer and known deleterious mutations in the BRCA 1 or 2 genes. In this highly specific cohort of women, the agent showed efficacy and was very well tolerated. Further studies using these new agents are under wa...
Trumpp and colleagues develop a method to obtain long-term circulating tumor cell-derived organoids from individuals with metastatic breast cancer and identify the neuregulin 1–HER3 axis as important for organoid growth and a promising therapeutic target. ...
The various agents differ greatly in their side-effect profiles and approved indications, from neoadjuvant and adjuvant use in early disease, to first- and later-line use in metastatic disease. This review discusses the current treatment recommendations for the use of anti-HER2 agents alone and in...
News & Views03 Dec 2024Nature Cancer Volume: 5, P: 1793-1795 Using tumor DNA methylomes to predict cancer metastasis to the brain Metastatic spread of cancer to the brain has a devastating effect on patient outcomes, yet identifying patients who will develop brain metastases is difficult in cur...
” According to this NHS, the cost of cancer treatment can now be slashed by up to three-quarters. They have called this cancer injection ‘anti-cancer injection,’ which requires seven minutes to administer completely. Read on to know the causes, warning signs, and latest treatment strategies...
monoclonal antibody, trastuzumab, for the treatment of patients with metastatic breast cancer.FDA has approved its use for patients with metastatic breast cancer with HER 2 over-expression since 1998, as a first line treatment in association with paclitaxel or as a second or third line monotherapy...
Dr. Edward Stadtmauer started off the webinar by providing an overview of treatments commonly employed in WM.He makes it clear that treatment for the disease generally is only initiated once a patient has begun experiencing pronounced signs or symptoms, such aschanges in platelets, anemia, thickene...
On March 8, 2019, the US Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab for first-line treatment of metastatic triple-negative breast... Blog-Breast Cancer-News-Science & Research Oral Paclitaxel With Encequidar Deemed Effective in Metastatic Breast Cancer, but Toxic...
Abiraterone acetate is used for the treatment of cancer, and it should be used with caution in patients who have a history of cardiovascular disease. Brentuximab vedotin is indicated for the treatment of Hodgkin lymphoma. Eribulin mesylate is indicated for the treatment of metastatic breast cancer....